Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry

View original at finance.yahoo.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry Company Logo With a focus on specialty medicines, growth is driven by pharmaceutical needs for cost-effective, efficient production and regulatory compliance via CDM…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • By February 2024, the global tally of registered clinical trials on ClinicalTrials.gov reached 483,592, marking a significant rise from the over 365,000 reported in early 2021. Of these, 66,206 trials are actively recruiting

    60% confidence

  • The global small molecule innovator API CDMO market is projected to expand significantly, with an estimated size of USD 26.66 billion in 2025, expected to reach USD 43.75 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033

    60% confidence

  • Small molecule applications constitute over half of specialty sales

    60% confidence

  • Only 11% of APIs are based in the U.S., with most sourced internationally

    60% confidence

  • Market expansion is fueled by a growing demand for small molecule drugs, an increase in outsourcing trends among pharmaceutical companies, and a surge in clinical trials

    60% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals46 novel_drugs
U.S. Food and Drug Administration · drug approvals50 novel_drugs
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry — Source | Via News | ViaNews Market